88427-96-7

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-METHYL-IMIDAZOL-1-YL)-BENZALDEHYDE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(2-METHYL-IMIDAZOL-1-YL)-BENZALDEHYDE is utilized as a building block in the creation of agrochemicals, playing a crucial role in the formulation of products designed to enhance crop protection and yield.
Used in Organic Chemistry Research:
4-(2-METHYL-IMIDAZOL-1-YL)-BENZALDEHYDE is employed as a reagent in organic chemistry reactions, particularly for the formation of heterocyclic compounds, which are essential in the development of complex organic molecules with diverse applications.
Used in the Synthesis of Organic Compounds:
As a versatile intermediate, 4-(2-METHYL-IMIDAZOL-1-YL)-BENZALDEHYDE is used in the synthesis of a broad spectrum of organic compounds, contributing to advancements in material science, chemical engineering, and related fields.

InChI:InChI=1/C11H10N2O/c1-9-12-6-7-13(9)11-4-2-10(8-14)3-5-11/h2-8H,1H3

Upstream product

• 693-98-1 2-methylimidazole 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 239073-26-8 4-(tert-butoxycarbonyl)-1-[4-(2-methyl-1H-imidazol-1-yl)benzyl]-2-piperazinone 
• 167758-58-9 4-(2-Methyl-1H-imidazol-1-yl)benzenemethanol 
• 1177252-04-8 1-{(1-benzyl-1H-tetrazol-5-yl)[4-(2-methyl-1H-imidazol-1-yl)phenyl]methyl}-4-cyclobutyl-1,4-diazepane 

Relevant academic research and scientific papers

Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes

GPR142 has been identified as a potential glucose-stimulated insulin secretion (GSIS) target for the treatment of type 2 diabetes mellitus (T2DM). A class of triazole GPR142 agonists was discovered through a high throughput screen. The lead compound 4 suffered from poor metabolic stability and poor solubility. Lead optimization strategies to improve potency, efficacy, metabolic stability, and solubility are described. This optimization led to compound 20e, which showed significant reduction of glucose excursion in wild-type but not in GPR142 deficient mice in an oral glucose tolerance test (oGTT) study. These studies provide strong evidence that reduction of glucose excursion through treatment with 20e is GPR142-mediated, and GPR142 agonists could be used as a potential treatment for type 2 diabetes.

Imidazole lipoxygenase inhibitors

Certain novel imidazole derivatives having the ability to inhibit the lipoxygenase enzyme and having formula (I), wherein Y is hydrogen, C1 -C8 alkyl, halosubstituted C1 -C4 alkyl, phenyl, substituted phenyl, C7 -C14 phenylalkyl, C7 -C14 (substituted phenyl)alkyl, pyridyl, substituted pyridyl, C6 -C13 pyridylalkyl or C6 -C13 (substituted pyridyl)alkyl, wherein each substituent is independently halo, nitro, cyano, C1 -C4 alkyl, C1 -C4 alkoxy, halosubstituted C1 -C4 alkyl, halosubstituted C1 -C4 alkoxy, NR4 R5, CO2 R4 or CONR4 R5, wherein R4 and R5 are each, independently, hydrogen or C1 -C6 alkyl; Ar1 and Ar2 are each, independently, phenylene, mono-substituted phenylene or di-substituted phenylene, wherein the substituents are, independently, halo, C1 -C4 alkyl, C1 -C4 alkoxy, halo-substituted C1 -C4 alkyl or halo-substituted C1 -C4 alkoxy; X and X1 are each, independently, O, S, SO or SO2 ; R' is hydrogen or C1 -C4 alkyl; and R2 and R3 are each, independently, methylene, ethylene or propylene. These compounds are useful for the treatment of disease states such as bronchial asthma, skin disorders and arthritis in mammals, and as the active ingredient in pharmaceutical compositions for treating such conditions.